Nielsen Fernandez-Becker, MD
Internal Medicine · Emeryville
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 10
- 2 carriers
- Offices
- 5
Offices
5 locations · Stanford Health Care · 3,152 clinicians in this group
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
10 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Fernandez-Becker’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
10 of 10 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A109586 · Current
Licensed to practise in California · since 2009 · expires 2027-03-31 · Albert Einstein College of Medicine of Yeshiva University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$61,378
Medicare paid this office $61,378 for 331 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 62 | $10,402 | $149 |
| New patient visit (60+ min) | 51 | $8,523 | $167 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 25 | $5,910 | $236 |
| Biopsy of large bowel using a flexible endoscope | 45 | $5,329 | $118 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $4,863 | $99 |
See all 15 services
| Long return visit (40+ min) | 62 | $10,402 | $149 |
| New patient visit (60+ min) | 51 | $8,523 | $167 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 25 | $5,910 | $236 |
| Biopsy of large bowel using a flexible endoscope | 45 | $5,329 | $118 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 47 | $4,863 | $99 |
| New patient visit (45+ min) | 34 | $4,454 | $131 |
| Return visit (30+ min) | 31 | $3,449 | $111 |
| Imaging of digestive tract done from the inside of the digestive tract | 20 | $2,713 | $136 |
| Study of esophagus to assess movement | 44 | $2,486 | $56 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 41 | $1,743 | $43 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 23 | $1,651 | $72 |
| New patient visit (30+ min) | 15 | $1,484 | $99 |
| Prolonged monitoring and recording of esophageal function through nasal tube with electrode | 13 | $646 | $50 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 18 | $289 | $8 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 39 | $186 | $5 |
Procedures Medicare counted
| Colonoscopy | 29 | More than 53% of doctors who do this |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 114 | More than 79% of doctors who do this |
Who their Medicare patients are
331 Original Medicare patients in 2024. Average age 71 · Under 65 13% · 85 and older 5% · Women 67% · Also on Medicaid 21% · Health risk score 1.30. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 56% · Coronary heart disease 23% · Depression 23% · Diabetes 22% · Chronic kidney disease 21% · Atrial fibrillation 17% · Cancer 16% · COPD 16% · Heart failure 12% · Stroke 9% · Dementia 4%.
The office billed $767,475, Medicare allowed $78,483 and paid $61,378; for 619 services of 38 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 331 | 619 | 71 | 1.30 | $767,475 | $61,378 |
| 2023 | 340 | 609 | 71 | 1.86 | $688,808 | $63,314 |
| 2022 | 297 | 544 | 70 | 1.97 | $561,601 | $57,748 |
| 2021 | 248 | 490 | 69 | 2.06 | $462,425 | $51,613 |
| 2020 | 216 | 437 | 69 | 1.55 | $383,799 | $38,005 |
| 2019 | 270 | 592 | 69 | 1.77 | $470,898 | $47,511 |
| 2018 | 242 | 539 | 68 | 2.04 | $383,667 | $45,941 |
| 2017 | 283 | 517 | 68 | 1.63 | $331,124 | $38,595 |
| 2016 | 309 | 495 | 69 | 1.69 | $366,855 | $41,383 |
| 2015 | 313 | 519 | 69 | 1.82 | $393,484 | $46,147 |
| 2014 | 264 | 443 | 68 | 1.65 | $313,756 | $43,013 |
| 2013 | 232 | 366 | 69 | 1.62 | $208,814 | $34,318 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 17 services
| New patient visit (60+ min) | 80 | $12,595 | $157 |
| Long return visit (40+ min) | 81 | $10,726 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 49 | $5,153 | $105 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 36 | $4,305 | $120 |
| Biopsy of large bowel using a flexible endoscope | 33 | $3,881 | $118 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | $2,793 | $215 |
| Imaging of digestive tract done from the inside of the digestive tract | 20 | $1,964 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $1,919 | $160 |
| Study of esophagus to assess movement | 26 | $1,533 | $59 |
| Return visit (30+ min) | 16 | $1,421 | $89 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 11 | $1,359 | $105 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,313 | $73 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 16 | $1,245 | $73 |
| New patient visit (45+ min) | 12 | $1,229 | $102 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 23 | $1,028 | $45 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 36 | $172 | $5 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 11 | $144 | $9 |
2022: 13 services
| Long return visit (40+ min) | 78 | $12,164 | $120 |
| New patient visit (60+ min) | 56 | $8,573 | $153 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 28 | $4,905 | $175 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 28 | $3,432 | $123 |
| Biopsy of large bowel using a flexible endoscope | 24 | $2,546 | $106 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 25 | $2,441 | $94 |
| Imaging of digestive tract done from the inside of the digestive tract | 21 | $2,200 | $105 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,828 | $102 |
| Study of esophagus to assess movement | 29 | $1,737 | $60 |
| Return visit (30+ min) | 17 | $1,449 | $76 |
| Monitoring and recording of esophageal function through a capsule attached to the esophagus wall | 12 | $888 | $74 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 14 | $634 | $45 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 25 | $103 | $4 |
2021: 13 services
| Long return visit (40+ min) | 46 | $7,515 | $134 |
| New patient visit (60+ min) | 47 | $7,339 | $156 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 23 | $4,256 | $185 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 30 | $3,262 | $99 |
| Biopsy of large bowel using a flexible endoscope | 17 | $2,692 | $158 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 21 | $2,606 | $67 |
| Return visit (30+ min) | 28 | $2,539 | $85 |
| New patient visit (45+ min) | 21 | $2,536 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $2,036 | $127 |
| Study of esophagus to assess movement | 25 | $1,513 | $61 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 15 | $1,386 | $92 |
| Short return visit (20+ min) | 15 | $876 | $58 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 23 | $115 | $5 |
2020: 11 services
| Long return visit (40+ min) | 66 | $7,915 | $101 |
| New patient visit (60+ min) | 38 | $5,138 | $135 |
| Return visit (30+ min) | 58 | $5,057 | $67 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $3,576 | $97 |
| New patient visit (45+ min) | 26 | $2,661 | $102 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 11 | $2,615 | $238 |
| Imaging of digestive tract done from the inside of the digestive tract | 18 | $2,182 | $121 |
| Biopsy of large bowel using a flexible endoscope | 18 | $1,990 | $111 |
| Study of esophagus to assess movement | 14 | $871 | $62 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 12 | $563 | $47 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 30 | $148 | $4 |
2019: 16 services
| Return visit (30+ min) | 57 | $4,711 | $65 |
| New patient visit (45+ min) | 38 | $4,271 | $112 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 29 | $3,145 | $108 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $3,056 | $85 |
| Long return visit (40+ min) | 31 | $2,997 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $2,838 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,723 | $124 |
| Study of esophagus to assess movement | 34 | $2,085 | $61 |
| New patient visit (60+ min) | 11 | $1,658 | $151 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,380 | $106 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 23 | $1,071 | $47 |
| Prolonged monitoring and recording of esophageal function through nasal tube with electrode | 13 | $686 | $53 |
| Short return visit (20+ min) | 13 | $597 | $46 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 30 | $294 | $9 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 28 | $126 | $4 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 18 | $88 | $5 |
2018: 13 services
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 62 | $7,577 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 44 | $5,230 | $65 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 34 | $3,282 | $94 |
| Return visit (30+ min) | 42 | $3,038 | $66 |
| Biopsy of large bowel using a flexible endoscope | 16 | $2,458 | $154 |
| Return visit (30+ min) | 30 | $2,446 | $70 |
| New patient visit (45+ min) | 19 | $2,168 | $114 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,167 | $103 |
| Long return visit (40+ min) | 11 | $1,097 | $100 |
| Long return visit (40+ min) | 11 | $1,086 | $99 |
| Study of esophagus to assess movement | 16 | $976 | $61 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 28 | $130 | $5 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 14 | $71 | $5 |
2017: 14 services
| Return visit (30+ min) | 70 | $6,183 | $65 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 40 | $4,450 | $109 |
| New patient visit (45+ min) | 35 | $3,844 | $110 |
| Long return visit (40+ min) | 35 | $3,441 | $96 |
| Imaging of digestive tract done from the inside of the digestive tract | 21 | $3,326 | $145 |
| Biopsy of large bowel using a flexible endoscope | 21 | $3,107 | $148 |
| Study of esophagus to assess movement | 34 | $1,950 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 15 | $1,831 | $122 |
| Short return visit (20+ min) | 27 | $1,202 | $41 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 11 | $1,166 | $65 |
| Monitoring and recording of esophageal function through nasal tube with electrode | 13 | $584 | $45 |
| Monitoring and recording of esophageal function through nasal tube | 11 | $506 | $46 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 29 | $241 | $8 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 47 | $230 | $5 |
2016: 14 services
| Imaging of digestive tract done from the inside of the digestive tract | 34 | $5,770 | $170 |
| New patient visit (45+ min) | 39 | $4,236 | $109 |
| Return visit (30+ min) | 48 | $3,746 | $67 |
| Biopsy of large bowel using a flexible endoscope | 23 | $3,529 | $153 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 35 | $3,339 | $95 |
| Study of esophagus to assess movement | 49 | $2,798 | $56 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,430 | $121 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 25 | $1,993 | $64 |
| Long return visit (40+ min) | 16 | $1,585 | $88 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,298 | $108 |
| Short return visit (20+ min) | 22 | $1,003 | $46 |
| Study of rectum sensitivity and function | 13 | $957 | $74 |
| Monitoring and recording of esophageal function through nasal tube | 15 | $648 | $43 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 51 | $472 | $9 |
2015: 13 services
| Imaging of digestive tract done from the inside of the digestive tract | 35 | $6,158 | $176 |
| New patient visit (45+ min) | 46 | $5,192 | $113 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 39 | $4,343 | $109 |
| Return visit (30+ min) | 54 | $4,207 | $68 |
| Study of esophagus to assess movement | 63 | $3,955 | $62 |
| Long return visit (40+ min) | 38 | $3,763 | $90 |
| Biopsy of large bowel using a flexible endoscope | 19 | $3,415 | $180 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $2,197 | $122 |
| Study of rectum sensitivity and function | 17 | $1,378 | $81 |
| Monitoring and recording of esophageal function through nasal tube | 25 | $1,146 | $46 |
| Short return visit (20+ min) | 18 | $820 | $46 |
| Prolonged monitoring and recording of esophageal function through nasal tube with electrode | 14 | $745 | $53 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 42 | $395 | $9 |
2014: 12 services
| New patient visit (45+ min) | 45 | $4,938 | $110 |
| Return visit (30+ min) | 53 | $4,755 | $67 |
| Imaging of digestive tract done from the inside of the digestive tract | 26 | $4,576 | $176 |
| Biopsy of large bowel using a flexible endoscope | 20 | $4,227 | $211 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 33 | $4,016 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 35 | $3,840 | $110 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $3,010 | $64 |
| Study of esophagus to assess movement | 31 | $1,913 | $62 |
| Long return visit (40+ min) | 16 | $1,677 | $93 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,253 | $104 |
| Study of rectum sensitivity and function | 11 | $843 | $77 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 27 | $240 | $9 |
2013: 9 services
| Return visit (30+ min) | 46 | $4,261 | $65 |
| Imaging of digestive tract done from the inside of the digestive tract | 25 | $4,209 | $156 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $3,515 | $130 |
| Long return visit (40+ min) | 35 | $3,468 | $83 |
| New patient visit (45+ min) | 35 | $3,359 | $96 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $3,083 | $119 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $1,428 | $62 |
| Study of rectum sensitivity and function | 18 | $1,409 | $78 |
| Measurement of hydrogen in breath to test for stomach and bowel symptoms | 31 | $294 | $9 |
Medicaid work
$2,515 in 2023
Medicaid paid $2,515 for 43 billed services this clinician did in 2023, up to 16 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 43 | $2,515 |
| 2023 | 43 | 1 | 16 | $2,515 |
Drugs they prescribed that Part D paid
$211,183
Pharmacies billed $211,183 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 432) in 2024. At or below the middle of the specialty; the typical internal medicine clinician is at 1%.
288 generic and 144 brand-name prescriptions · $211,183 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Dupixent | 15 | $79,519 | $5,301 |
| Creon | 21 | $38,068 | $1,813 |
| Motegrity | 24 | $26,679 | $1,112 |
| Linzess | 38 | $25,774 | $678 |
| Omeprazole | 92 | $1,660 | $18 |
See all 11 drugs
| Dupixent | 15 | $79,519 | $5,301 |
| Creon | 21 | $38,068 | $1,813 |
| Motegrity | 24 | $26,679 | $1,112 |
| Linzess | 38 | $25,774 | $678 |
| Omeprazole | 92 | $1,660 | $18 |
| Famotidine | 45 | $847 | $19 |
| Peg 3350-Electrolyte | 32 | $644 | $20 |
| Pantoprazole | 13 | $259 | $20 |
| Gavilyte-G | 15 | $223 | $15 |
| Nortriptyline | 17 | $221 | $13 |
| Peg-3350 and Electrolytes | 11 | $190 | $17 |
Year by year
| 2024 | 432 | 146 | 0% (0) | 33% | $211,183 |
| 2023 | 424 | 150 | 0% (0) | 22% | $110,483 |
| 2022 | 399 | 114 | 0% (0) | None | $80,051 |
| 2021 | 356 | 100 | 0% (0) | None | $86,427 |
| 2020 | 471 | 126 | 0% (0) | None | $107,734 |
| 2019 | 342 | 102 | 0% (0) | None | $50,967 |
| 2018 | 349 | 87 | 0% (0) | 16% | $37,508 |
| 2017 | 412 | 130 | 0% (0) | None | $51,654 |
| 2016 | 278 | 86 | 0% (0) | None | $20,878 |
| 2015 | 400 | 95 | 0% (0) | None | $27,620 |
| 2014 | 334 | 83 | None | None | $20,738 |
| 2013 | 338 | 82 | None | 20% | $34,541 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 10 drugs
| Creon | 16 | $36,134 | $2,258 |
| Linzess | 26 | $20,708 | $796 |
| Lubiprostone | 17 | $2,583 | $152 |
| Omeprazole | 94 | $2,039 | $22 |
| Famotidine | 47 | $1,323 | $28 |
| Peg 3350-Electrolyte | 30 | $678 | $23 |
| Gavilyte-G | 22 | $363 | $16 |
| Buspirone | 11 | $357 | $32 |
| Nortriptyline | 29 | $320 | $11 |
| Pantoprazole | 15 | $288 | $19 |
2022: 11 drugs
| Creon | 16 | $38,980 | $2,436 |
| Linzess | 27 | $13,648 | $505 |
| Esomeprazole Magnesium | 16 | $4,068 | $254 |
| Lubiprostone | 15 | $2,589 | $173 |
| Omeprazole | 77 | $1,522 | $20 |
| Famotidine | 43 | $1,058 | $25 |
| Peg 3350-Electrolyte | 28 | $601 | $21 |
| Pantoprazole | 35 | $318 | $9 |
| Ondansetron Odt | 11 | $232 | $21 |
| Gabapentin | 12 | $127 | $11 |
| Nortriptyline | 11 | $104 | $9 |
2021: 7 drugs
| Creon | 13 | $26,196 | $2,015 |
| Linzess | 20 | $12,814 | $641 |
| Esomeprazole Magnesium | 17 | $2,164 | $127 |
| Omeprazole | 101 | $2,139 | $21 |
| Famotidine | 39 | $1,080 | $28 |
| Pantoprazole | 38 | $605 | $16 |
| Peg 3350-Electrolyte | 11 | $167 | $15 |
2020: 9 drugs
| Xifaxan | 12 | $19,402 | $1,617 |
| Linzess | 18 | $13,873 | $771 |
| Trulance | 14 | $10,671 | $762 |
| Esomeprazole Magnesium | 35 | $7,437 | $212 |
| Omeprazole | 97 | $1,671 | $17 |
| Famotidine | 56 | $1,212 | $22 |
| Pantoprazole | 37 | $573 | $15 |
| Buspirone | 15 | $265 | $18 |
| Gavilyte-G | 17 | $245 | $14 |
2019: 7 drugs
| Amitiza | 19 | $8,826 | $465 |
| Omeprazole | 67 | $845 | $13 |
| Ranitidine | 31 | $520 | $17 |
| Pantoprazole | 36 | $459 | $13 |
| Famotidine | 19 | $418 | $22 |
| Gabapentin | 11 | $237 | $22 |
| Gavilyte-G | 12 | $175 | $15 |
2018: 9 drugs
| Linzess | 15 | $6,709 | $447 |
| Polyethylene Glycol 3350 | 20 | $1,158 | $58 |
| Omeprazole | 48 | $837 | $17 |
| Pantoprazole | 38 | $728 | $19 |
| Ranitidine | 61 | $576 | $9 |
| Loperamide | 14 | $351 | $25 |
| Gabapentin | 15 | $165 | $11 |
| Famotidine | 14 | $164 | $12 |
| Gavilyte-G | 13 | $150 | $12 |
2017: 11 drugs
| Linzess | 27 | $9,646 | $357 |
| Amitiza | 11 | $3,870 | $352 |
| Polyethylene Glycol 3350 | 14 | $2,004 | $143 |
| Pantoprazole | 42 | $837 | $20 |
| Omeprazole | 70 | $787 | $11 |
| Loperamide | 15 | $380 | $25 |
| Ranitidine | 36 | $352 | $10 |
| Gabapentin | 24 | $262 | $11 |
| Peg 3350-Electrolyte | 15 | $203 | $14 |
| Gavilyte-N | 11 | $202 | $18 |
| Peg-3350 and Electrolytes | 13 | $198 | $15 |
2016: 6 drugs
| Pantoprazole | 37 | $518 | $14 |
| Omeprazole | 54 | $479 | $9 |
| Gabapentin | 18 | $396 | $22 |
| Ranitidine | 27 | $268 | $10 |
| Baclofen | 12 | $158 | $13 |
| Dicyclomine | 12 | $93 | $8 |
2015: 9 drugs
| Ondansetron | 11 | $2,808 | $255 |
| Omeprazole | 85 | $870 | $10 |
| Pyridostigmine | 11 | $615 | $56 |
| Gabapentin | 30 | $562 | $19 |
| Polyethylene Glycol 3350 | 11 | $556 | $51 |
| Pantoprazole | 37 | $497 | $13 |
| Ranitidine | 42 | $345 | $8 |
| Peg 3350-Electrolyte | 18 | $314 | $17 |
| Nortriptyline | 18 | $185 | $10 |
2014: 9 drugs
| Nexium | 16 | $5,149 | $322 |
| Omeprazole | 69 | $1,237 | $18 |
| Gabapentin | 31 | $683 | $22 |
| Polyethylene Glycol 3350 | 24 | $536 | $22 |
| Pantoprazole | 27 | $334 | $12 |
| Nortriptyline | 23 | $334 | $15 |
| Pyridostigmine | 13 | $322 | $25 |
| Ranitidine | 24 | $209 | $9 |
| Famotidine | 21 | $182 | $9 |
2013: 9 drugs
| Nexium | 15 | $7,028 | $469 |
| Omeprazole | 43 | $1,123 | $26 |
| Pantoprazole | 24 | $713 | $30 |
| Polyethylene Glycol 3350 | 24 | $676 | $28 |
| Gabapentin | 13 | $407 | $31 |
| Nortriptyline | 38 | $346 | $9 |
| Dicyclomine | 13 | $252 | $19 |
| Ranitidine | 18 | $204 | $11 |
| Famotidine | 16 | $196 | $12 |
Money from drug and device companies
$72 in 2025
| 2025 | 2 | 3 | None | $72 |
| 2024 | 1 | 1 | None | $134 |
| 2023 | 1 | 1 | None | $129 |
| 2020 | 1 | 6 | None | $1,545 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boston Scientific | General - Gi Dilatation | $43 | 2 payments
|
| Mauna Kea Technologies | None | $29 | 1 payment
|
See all 3 published payments
| Mauna Kea Technologies | Meals · 2025-07-21 | None | $29 |
| Boston Scientific | Meals · 2025-05-09 | General - Gi Dilatation | $25 |
| Boston Scientific | Meals · 2025-05-09 | General - Gi Dilatation | $18 |
See earlier years (2024, 2023, 2020)
2024: $134
| AnX Robotica | None | $134 | 1 payment
|
2023: $129
| AnX Robotica | None | $129 | 1 payment
|
2020: $1,545
| Adare Pharmaceuticals | None | $1,545 | 6 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| ImmunogenX, Inc. · A Clinical Study of Latiglutenase As A Treatment for Symptom Reduction for Celiac Disease · 2023 | Their institution | $180,002 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Tak-062 in Treatment of Active Celiac Disease in Participants Attempting A Gluten-Free Diet · 2023 | Their institution | $50,144 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Tak-062 in Treatment of Active Celiac Disease in Participants Attempting A Gluten-Free Diet · 2024 | Their institution | $23,268 |
| Regeneron Pharmaceuticals, Inc. · A Phase 3, Randomized, 3-Part Study To Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis Eoe · 2019 | Their institution | $21,017 |
| Takeda Pharmaceuticals U.S.A., Inc. · A Study of Tak-062 in Treatment of Active Celiac Disease in Participants Attempting A Gluten-Free Diet · 2025 | Their institution | $2,974 |
Professional record
- NPI
- 1972678639
- Licence
- CA A109586California A109586: Current · expires 2027-03-31
- Trained
- Albert Einstein College of Medicine of Yeshiva University, 2002
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94304
- NPI first listed
- 2006-11-21
- NPI last updated
- 2024-04-29
- NPI record certified
- 2024-04-29
This is when the NPI record was last certified, not a medical board exam.